During the recent session, Arcutis Biotherapeutics Inc (NASDAQ:ARQT)’s traded shares were 1.22 million, with the beta value of the company hitting 1.50. At the last check today, the stock’s price was $12.05, reflecting an intraday loss of -8.82% or -$1.16. The 52-week high for the ARQT share is $16.20, that puts it down -34.44 from that peak though still a striking 49.79% gain since the share price plummeted to a 52-week low of $6.05. The company’s market capitalization is $1.41B, and the average intraday trading volume over the past 10 days was 2.46 million shares, and the average trade volume was 2.10 million shares over the past three months.
Arcutis Biotherapeutics Inc (ARQT) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.25. ARQT has a Sell rating from 1 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.26.
Arcutis Biotherapeutics Inc (NASDAQ:ARQT) trade information
Arcutis Biotherapeutics Inc (ARQT) registered a -8.82% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -8.82% in intraday trading to $12.05, hitting a weekly high. The stock’s 5-day price performance is -3.02%, and it has moved by -9.30% in 30 days. Based on these gigs, the overall price performance for the year is 80.04%. The short interest in Arcutis Biotherapeutics Inc (NASDAQ:ARQT) is 18.91 million shares and it means that shorts have 9.95 day(s) to cover.
The consensus price target of analysts on Wall Street is $19, which implies an increase of 36.58% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $19 and $19 respectively. As a result, ARQT is trading at a discount of -57.68% off the target high and -57.68% off the low.
Arcutis Biotherapeutics Inc (ARQT) estimates and forecasts
In the rating firms’ projections, revenue will increase 211.19% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 60.52M as predicted by 7 analyst(s). Meanwhile, a consensus of 4 analyst(s) estimates revenue growth to 63.19M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 13.53M and 49.57M respectively. In this case, analysts expect current quarter sales to grow by 347.41% and then jump by 27.48% in the coming quarter.
ARQT Dividends
Arcutis Biotherapeutics Inc is due to release its next quarterly earnings in March. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Arcutis Biotherapeutics Inc (NASDAQ:ARQT)’s Major holders
The next largest institutional holding, with 10.0 million shares, is of SUVRETTA CAPITAL MANAGEMENT, LLC’s that is approximately 8.1021% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $93.04 million.
Also, the Mutual Funds coming in first place with the largest holdings of Arcutis Biotherapeutics Inc (ARQT) shares are Vanguard Total Stock Market Index Fund and PGIM Jennison Small Company Fd. Data provided on Sep 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 3.59 shares. This amounts to just over 3.07 percent of the company’s overall shares, with a $42.18 million market value. The same data shows that the other fund manager holds slightly less at 3.09, or about 2.64% of the stock, which is worth about $36.25 million.
